Psychiatry · Medical Literature
Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial.
Abstract
The effectiveness of pharmacogenetics to guide prescribing of selective serotonin reuptake inhibitors (SSRIs) for depression remains unclear, despite the well-established association between SSRI pharmacokinetics and genetic variation. To determine whether pharmacogenetic-guided prescribing of SSRIs improves treatment response in patients with depression. The ADOPT PGx (A Depression and Opioid Pragmatic Trial in Pharmacogenetics) Depression pragmatic randomized clinical trial was conducted from August 10, 2021, through April 27, 2024, at primary care, psychiatry, or family medicine clinics at enrolling sites throughout the US. Patients were aged 8 years or older and had experienced depression for 3 months or longer. Patients were randomized to genotype-guided SSRI prescribing (intervention group) or usual care (control group). Actionable drug metabolism phenotypes were defined as those for which pharmacogenetic clinical guidelines recommend alternative medication selection or dose adjustment. The primary outcome was change in Patient-Reported Outcomes Measurement Information System (PROMIS) depression T scores at 3 months among patients with the actionable phenotype. Secondary end points included adverse effect severity of SSRIs at 3 months and depression remission (measured with PROMIS depression scores and Patient Health Questionnaire-8 [PHQ-8] scores) at 6 months. This study of 1460 patients included 1239 adults (84.9%) (mean [SD] age, 40.6 [16.7] years) and 221 children (15.1%) (mean [SD] age, 14.6 [1.8] years). Most patients were female (1096 [75.1%]). A total of 692 patients (47.4%) had an actionable phenotype; 351 (50.7%) were assigned to the intervention, and 341 (49.3%) were assigned to usual care. At baseline, 463 of the 692 patients (66.9%) reported having depressive symptoms for more than 2 years, 603 (87.1%) were receiving pharmacologic treatment, and 354 (51.2%) were receiving nonpharmacologic treatment. At 3 months, no significant differences were observed between the intervention and usual care groups in change in PROMIS depression T scores (mean [SD] change, -4.3 [8.4] vs -4.0 [8.1]; P = .68), medication adverse effect burden (mean [SD] change, 8.2 [4.3] vs 7.8 [4.5]; P = .37), or Patient Health Questionnaire-8 score change (mean [SD] change, -3.3 [5.2] vs -2.7 [4.8]; P = .13). However, at 6 months, the PROMIS depression T-score remission rate (score ≤16) was higher in the intervention group compared with the usual care group (153 of 317 patients [48.3%] vs 122 of 310 patients [39.4%]; P = .02). In this randomized clinical trial, genotype-guided prescribing of SSRIs did not improve control of depression symptoms at 3 months compared with usual care but was associated with higher depression remission rates at 6 months. These findings suggest a possible longer-term clinical benefit and indicate that future studies should focus on the durability and long-term impact of genotype-guided prescribing in the management of depressive symptoms. ClinicalTrials.gov Identifiers: NCT04445792 (Master Protocol Research Program platform trial) and NCT05966155 (ADOPT PGx Depression trial).
Clinical relevance
Does pharmacogenetic-guided SSRI prescribing, based on CYP2D6 and CYP2C19 genotyping, improve depression symptom control compared with usual care in patients aged 8 years or older with an actionable drug metabolism phenotype? __SNAPSHOT__ {"studyDesign":"Pragmatic, multicenter, two-arm randomized clinical trial (ADOPT PGx Depression trial, part of the IGNITE Pragmatic Trials Network)","setting":"Primary care, psychiatry, and family medicine clinics across nine US health systems; August 2021 – April 2024","sampleSize":"n=1,460 enrolled (1,239 adults, 221 children); primary analysis restricted to n=692 patients with an actionable phenotype (intervention: n=351, usual care: n=341)","population":"Patients aged ≥8 years with depression lasting ≥3 months; 75.1% female; 65.6% White/European American; 15.8% Black/African American; mean adult age 40.6 years; mean child age 14.6 years; 87.1% on pharmacologic treatment at baseline; ~66.9% with depressive symptoms >2 years; mean baseline PROMIS depression T-score 61.5; mean baseline PHQ-8 score 12.6. Exclusions included active psychosis, dementia, and neurocognitive developmental disorders.","intervention":"Immediate CYP2D6 and CYP2C19 genotyping with genotype-guided SSRI prescribing recommendations informed by Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines; actionable phenotypes triggered alternative medication selection or dose adjustment","comparator":"Usual care (delayed genotyping at 6 months; standard clinical prescribing without pharmacogenetic input during the primary observation period)","primaryOutcome":"Change in PROMIS Depression T-score from baseline to 3 months in the actionable-phenotype subgroup","followUp":"6 months (primary endpoint at 3 months; key secondary endpoints at 6 months)","fundingSource":"Not explicitly reported in abstract; trial conducted under the IGNITE Pragmatic Trials Network; no competing interests declared by authors in the design paper"}
Key findings
PRIMARY OUTCOME (3 months, actionable-phenotype subgroup): Genotype-guided prescribing did not significantly improve PROMIS Depression T-scores at 3 months compared with usual care. Mean PROMIS T-score at 3 months was 57.0 (intervention) vs 57.5 (usual care); mean difference −0.3; p=0.67. Mean change from baseline was −4.3 (SD 8.4) vs −4.0 (SD 8.1); p=0.68. There was also no significant difference in PHQ-8 score change or proportion of patients with ≥50% PHQ-8 reduction at 3 months. SSRI adverse effect burden did not differ significantly between groups at 3 months. SECONDARY OUTCOME (6 months): PROMIS-defined remission (T-score ≤16) was significantly higher in the intervention group: 48.3% (153/317) vs 39.4% (122/310); absolute risk difference +8.9 percentage points (95% CI, 1.2%–16.6%); p=0.02. NNT for PROMIS remission at 6 months: approximately 11 (calculated). PHQ-8–defined remission also favored the intervention: 29.9% vs 21.0%; absolute risk difference +8.8 percentage points (95% CI, 2.1%–15.6%); p=0.01. NNT for PHQ-8 remission at 6 months: approximately 11 (calculated). Notably, only 47.4% of the total enrolled sample had an actionable phenotype, meaning the majority of genotyped patients did not receive a CPIC-recommended prescribing change.
Practice implications
This trial established that genotype-guided SSRI prescribing (CYP2D6/CYP2C19) does NOT improve short-term (3-month) symptom control or SSRI adverse effect burden compared with usual care in patients with an actionable phenotype. The positive 6-month remission signal is a secondary, hypothesis-generating finding and should be interpreted cautiously: it was not the pre-specified primary endpoint, and secondary endpoints carry a higher risk of false positives. The absolute remission benefit (~9 percentage points) is clinically modest, and NNT ~11 means roughly 10 of 11 patients with an actionable phenotype who undergo genotyping will not achieve remission that they would not have achieved with usual care. Findings apply specifically to patients with CYP2D6/CYP2C19 actionable phenotypes receiving SSRIs in US mixed-specialty ambulatory settings; they cannot be generalized to patients without actionable phenotypes (~52.6% of this cohort) or to non-SSRI antidepressants. The population included children (15%), making this one of few pediatric-inclusive pharmacogenetic RCTs, though subgroup results by age are not separately reported here. The trial also did not establish that the mechanism of benefit is purely pharmacokinetic—placebo or behavioral effects from knowledge of genetic testing cannot be ruled out in this unblinded design. Contradictory directionality of benefit (early vs. late) compared with the PRIME Care trial further complicates interpretation. Practice change is not warranted based solely on these data; confirmatory longer-term trials are needed. Only an abstract and secondary sources were available for this summary. __LIMITATIONS__ Open-label pragmatic design: neither patients nor clinicians could be blinded to genotype-guided vs. usual care assignment, introducing substantial risk of performance bias, expectation effects, and clinician behavior change that may inflate the secondary outcome,The primary outcome (3-month PROMIS change) was negative; the statistically significant 6-month remission finding is a secondary endpoint subject to multiple comparison risk and cannot be considered confirmatory,Maximum follow-up was only 6 months; durability of any remission benefit beyond this period is entirely unknown,Incomplete pharmacogenetically concordant prescribing in some intervention-arm patients (noted by authors) introduces exposure misclassification that biases results toward the null,COVID-19 pandemic disrupted enrollment, treatment delivery, and follow-up assessments, introducing additional noise and potential selection bias,Variability in clinical practice across nine health systems may affect generalizability of implementation findings,The sample was 65.6% White/European American; generalizability to other populations with potentially different allele frequencies is limited,Children (aged 8–17) were included but age-stratified efficacy results are not reported in the abstract, limiting pediatric-specific conclusions,The PROMIS remission threshold (T-score ≤16) represents a very low depression burden; the clinical meaningfulness of this endpoint definition warrants scrutiny,Contradictory findings with prior large RCT (PRIME Care: early benefit that attenuated over time vs. ADOPT PGx: no early benefit but late signal) undermine confidence in either result,Funding source not clearly reported in the abstract; absence of disclosed industry sponsorship is noted but cannot be confirmed __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ In the ADOPT PGx Depression trial, genotype-guided CYP2D6/CYP2C19-based SSRI prescribing did not improve depressive symptom control at 3 months (the primary endpoint) or reduce adverse effect burden compared with usual care in patients with an actionable pharmacogenetic phenotype. A secondary finding of modestly higher remission rates at 6 months (NNT ~11, calculated) is hypothesis-generating but insufficient to change practice given the open-label design, multiple comparison risk, and contradictory evidence from prior large trials. Clinicians should await confirmatory long-term RCTs before routinely implementing pharmacogenetic-guided SSRI selection outside of research or specialized clinical contexts.